2004
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non–small-cell lung cancer: report of a randomized comparative trial
Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non–small-cell lung cancer: report of a randomized comparative trial. International Journal Of Radiation Oncology • Biology • Physics 2004, 58: 1369-1377. PMID: 15050312, DOI: 10.1016/j.ijrobp.2003.10.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAgranulocytosisAmifostineAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCisplatinCombined Modality TherapyConfidence IntervalsEtoposideFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedRadiation PneumonitisRadiation-Protective AgentsRadiotherapy DosageSurvival AnalysisTreatment OutcomeConceptsArm 2 patientsCell lung cancerArm 1 patientsLung cancerArm 1Concurrent chemotherapyNational Cancer Institute Common Toxicity CriteriaConcurrent cisplatin-based chemotherapyAbility of amifostineCommon Toxicity CriteriaCisplatin-based chemotherapyTumor-protective effectMedian survival timeEffects of amifostineAcute toxicityEsophageal toxicityNeutropenic feverOral etoposideConcurrent chemoradiotherapyHematologic toxicityMild hypotensionThoracic radiotherapyLiving patientsSevere pneumonitisTumor characteristics
2002
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results
Komaki R, Lee J, Kaplan B, Allen P, Kelly J, Liao Z, Stevens C, Fossella F, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames H, Hong W, Cox J. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results. Seminars In Radiation Oncology 2002, 12: 46-49. PMID: 11917284, DOI: 10.1053/srao.2002.31363.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerThoracic radiation therapyInoperable stage IICell lung cancerSevere esophagitisArm 2Arm 1Lung cancerDay 1Randomized phase III studyStage IIPhase III studyGy/fractionMedian survival timeLong-term efficacyOral etoposideAcute pneumonitisConcurrent chemoradiotherapyIII studyTumor characteristicsPulmonary toxicityStudy groupRadiation therapyDay 29Survival time